Sagimet Biosciences Inc
SGMT6.240USD
-0.040-0.64%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
202.93MMarket Cap
LossP/E TTM
More Details of Sagimet Biosciences Inc Company
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Sagimet Biosciences Inc Info
Ticker SymbolSGMT
Company nameSagimet Biosciences Inc
IPO dateJul 14, 2023
CEOHappel (David)
Number of employees14
Security typeOrdinary Share
Fiscal year-endJul 14
Address155 Bovet Rd., Suite 303
CitySAN MATEO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94402
Phone16505618600
Websitehttps://sagimet.com/
Ticker SymbolSGMT
IPO dateJul 14, 2023
CEOHappel (David)
Company Executives of Sagimet Biosciences Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
193.58K
+5.36%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.04K
-38.40%
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.76K
-58.97%
Dr. George Kemble, Ph.D.
Dr. George Kemble, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
5.63K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
2.20K
--
Mr. Paul W. Hoelscher
Mr. Paul W. Hoelscher
Independent Director
Independent Director
--
--
Mr. Thierry Chauche
Mr. Thierry Chauche
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Ms. Elizabeth Grammer, Esq.
Ms. Elizabeth Grammer, Esq.
Independent Director
Independent Director
--
--
Dr. Anne M. Phillips, M.D.
Dr. Anne M. Phillips, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Elizabeth Rozek
Ms. Elizabeth Rozek
Chief Compliance Officer, General Counsel
Chief Compliance Officer, General Counsel
193.58K
+5.36%
Dr. Beth C. Seidenberg, M.D.
Dr. Beth C. Seidenberg, M.D.
Independent Director
Independent Director
131.64K
--
Mr. David Happel
Mr. David Happel
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.04K
-38.40%
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Dr. Eduardo Bruno Martins, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
5.76K
-58.97%
Dr. George Kemble, Ph.D.
Dr. George Kemble, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
5.63K
--
Mr. Timothy P. (Tim) Walbert
Mr. Timothy P. (Tim) Walbert
Independent Director
Independent Director
2.20K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Dec 21
Updated: Sun, Dec 21
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
AP11 Limited
4.85%
Woodline Partners LP
4.84%
Blue Owl Capital Holdings LP
4.28%
The Vanguard Group, Inc.
3.88%
Baker Bros. Advisors LP
3.07%
Other
79.06%
Shareholders
Shareholders
Proportion
AP11 Limited
4.85%
Woodline Partners LP
4.84%
Blue Owl Capital Holdings LP
4.28%
The Vanguard Group, Inc.
3.88%
Baker Bros. Advisors LP
3.07%
Other
79.06%
Shareholder Types
Shareholders
Proportion
Hedge Fund
17.44%
Investment Advisor
14.67%
Investment Advisor/Hedge Fund
6.70%
Corporation
5.10%
Research Firm
1.85%
Individual Investor
1.47%
Venture Capital
0.19%
Bank and Trust
0.03%
Other
52.54%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
201
11.98M
29.92%
-9.02M
2025Q2
201
17.99M
58.65%
-8.78M
2025Q1
199
18.50M
63.07%
-6.39M
2024Q4
183
22.20M
72.39%
-4.47M
2024Q3
166
24.34M
79.36%
-2.24M
2024Q2
157
25.83M
85.10%
-301.40K
2024Q1
134
27.23M
89.77%
+13.80M
2023Q4
94
18.02M
81.13%
+2.10M
2023Q3
73
15.74M
73.17%
+13.03M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
AP11 Limited
1.50M
3.76%
-150.06K
-9.07%
Jun 24, 2025
Woodline Partners LP
2.55M
6.38%
+2.55M
--
Jun 30, 2025
Blue Owl Capital Holdings LP
1.33M
3.32%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
1.15M
2.88%
--
--
Jun 30, 2025
Baker Bros. Advisors LP
953.00K
2.38%
--
--
Jun 30, 2025
HHLR Advisors, Ltd.
724.80K
1.81%
--
--
Jun 30, 2025
Invus Public Equities Advisors, LLC
724.77K
1.81%
--
--
Jun 30, 2025
D. E. Shaw & Co., L.P.
143.85K
0.36%
+143.85K
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Growth ETF
0%
iShares Health Innovation Active ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Global X Russell 2000 ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.03%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Sagimet Biosciences Inc?
The top five shareholders of Sagimet Biosciences Inc are:
AP11 Limited holds 1.50M shares, accounting for 3.76% of the total shares.
Woodline Partners LP holds 2.55M shares, accounting for 6.38% of the total shares.
Blue Owl Capital Holdings LP holds 1.33M shares, accounting for 3.32% of the total shares.
The Vanguard Group, Inc. holds 1.15M shares, accounting for 2.88% of the total shares.
Baker Bros. Advisors LP holds 953.00K shares, accounting for 2.38% of the total shares.
AP11 Limited holds 1.50M shares, accounting for 3.76% of the total shares.
Woodline Partners LP holds 2.55M shares, accounting for 6.38% of the total shares.
Blue Owl Capital Holdings LP holds 1.33M shares, accounting for 3.32% of the total shares.
The Vanguard Group, Inc. holds 1.15M shares, accounting for 2.88% of the total shares.
Baker Bros. Advisors LP holds 953.00K shares, accounting for 2.38% of the total shares.
What are the top three shareholder types of Sagimet Biosciences Inc?
The top three shareholder types of Sagimet Biosciences Inc are:
AP11 Limited
Woodline Partners LP
Blue Owl Capital Holdings LP
AP11 Limited
Woodline Partners LP
Blue Owl Capital Holdings LP
How many institutions hold shares of Sagimet Biosciences Inc (SGMT)?
As of 2025Q3, 201 institutions hold shares of Sagimet Biosciences Inc, with a combined market value of approximately 11.98M, accounting for 29.92% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -28.73%.
What is the biggest source of revenue for Sagimet Biosciences Inc?
In --, the -- business generated the highest revenue for Sagimet Biosciences Inc, amounting to -- and accounting for --% of total revenue.
